Comparative Pharmacology
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus TAB PROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus TAB PROFEN.
FLURBIPROFEN SODIUM vs TAB-PROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor; reduces prostaglandin synthesis.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
400-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
The terminal elimination half-life is 2-4 hours in adults with normal renal function. In elderly patients or those with renal impairment, half-life may be prolonged up to 8-12 hours, requiring dose adjustment.
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Renal excretion of unchanged drug accounts for approximately 70-90% of the administered dose, with the remainder eliminated as glucuronide conjugates in urine. Biliary/fecal elimination is minimal (<5%).
Category D/X
Category C
NSAID
NSAID